Corvus Pharmaceuticals/$CRVS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
- Ticker
- $CRVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 37
- Headquarters
- South San Francisco, United States
- Website
- www.corvuspharma.com
CRVS Metrics
BasicAdvanced
$844M
-
-$0.62
0.87
-
Price and volume
Market cap
$844M
Beta
0.87
52-week high
$26.95
52-week low
$6.39
Average daily volume
1.1M
Financial strength
Current ratio
16.162
Quick ratio
15.877
Long term debt to equity
0.001
Total debt to equity
0.003
Profitability
EBITDA (TTM)
-56.846
Management effectiveness
Return on assets (TTM)
-21.66%
Return on equity (TTM)
-35.43%
Valuation
Price to book
3.74
Price to tangible book (TTM)
3.74
Price to free cash flow (TTM)
-19.311
Free cash flow yield (TTM)
-5.18%
Free cash flow per share (TTM)
-0.519
Growth
Earnings per share change (TTM)
-38.47%
3-year earnings per share growth (CAGR)
-9.28%
10-year earnings per share growth (CAGR)
-17.73%
What the Analysts think about CRVS
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
Analyst projections of the future price of Corvus Pharmaceuticals stock.
Bulls say / Bears say
In the Phase 1 atopic dermatitis study, 75% of patients in the highest-dose cohort achieved EASI-75, with no serious adverse events reported. The encouraging signal, including signs of lasting benefit after treatment stopped, gives soquelitinib a potential route into a large inflammatory-disease market. (Corvus Pharmaceuticals)
In a Phase 1/1b T-cell lymphoma study, 9 of 24 patients treated at the selected dose who had received one to three prior therapies responded, including six complete responses. Soquelitinib is now being tested in a registrational Phase 3 trial for relapsed or refractory PTCL, where treatment options remain limited. (Corvus Pharmaceuticals)
Corvus had $215.2 million in cash, cash equivalents and marketable securities at the end of June 2026, which it expects to fund operations into the second quarter of 2028. That provides near-term funding for its Phase 3 lymphoma and Phase 2 dermatitis programmes without an immediate need for another raise. (SEC)
The dermatitis efficacy signal comes from a small Phase 1 study: the highest-dose cohort had only 24 patients split between drug and placebo, and treatment lasted eight weeks. The larger Phase 2 trial is still under way, with top-line results expected in the third quarter of 2027, so the early results may not hold up at scale. (SEC, Benzinga)
The lymphoma response evidence is early and concentrated in a selected subgroup: 9 of 24 patients with one to three prior therapies responded, while the study reported no responses among patients with more than three prior treatments. The key test is whether the benefit translates into better progression-free survival in the ongoing randomised Phase 3 trial. (Blood Cancer Research WA, Corvus Pharmaceuticals)
Corvus has no product-sales revenue and has accumulated substantial losses; its own filing says it will need additional capital to fund development through commercialisation. Future equity financing could dilute shareholders, while trial or regulatory setbacks could make funding more difficult or expensive. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
CRVS Financial Performance
Revenues and expenses
CRVS Earnings Performance
Company profitability
Upcoming events
No upcoming events
CRVS News
AllArticlesVideos
Funds containing CRVS
Fund name | Fund size | $CRVS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.